CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
CHARM Therapeutics has raised $20.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2023.
CHARM Therapeutics's investors include General Catalyst, Khosla Ventures, OrbiMed, F-Prime Capital, NVentures.
CHARM Therapeutics is headquartered in London, United Kingdom.
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
CHARM Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CHARM Therapeutics — Funding & Investors." VCBacked, April 14, 2023, https://www.vcbacked.co/company/charm-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). CHARM Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/charm-therapeutics
{{cite web |title=CHARM Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/charm-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated